| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5727470 | Journal of Vascular and Interventional Radiology | 2017 | 9 Pages |
Abstract
Patients with HCC treated with transarterial chemoembolization experienced a significant survival advantage compared with those not treated with transarterial chemoembolization. More than 75% of SEER/Medicare patients diagnosed with HCC received no identifiable oncologic treatment. There is a significant public health need to increase awareness of efficacious HCC treatments such as transarterial chemoembolization.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Stephen H. MD, Jared A. MD, Peng PhD, Meredith L. PhD, David T. PhD, Ahmed K. MD, PhD, Heather N. MD, Brendan MD, Devin E. MD, Derek A. MD,